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Introduction
Inflammatory bowel diseases (IBD) are a group of 
immunity-driven conditions characterized by the 
presence of flares intertwined with remission peri-
ods. These conditions include Crohn’s disease 
(CD) and ulcerative colitis (UC), and are thought 
to arise from a complex interplay involving envi-
ronmental and immunological factors on a suscep-
tible genetic background. Tumour necrosis factor 
α (TNFα) is a key cytokine that plays a major role 
in IBD pathophysiology.1 The development of 
anti-TNFα monoclonal antibodies has therefore 
revolutionized the therapeutic approach and natu-
ral progression of IBD: the utilization of these bio-
logical therapies led to decreased rates of steroid 
utilization, surgery and hospitalization, increased 
rates of clinical remission and mucosal healing, 
and an overall improvement in the health-related 
quality of life of IBD patients.2–4 Four different 
anti-TNFα agents are currently being used for the 
treatment of IBD, of which infliximab (name 
brand Remicade®,  Remicade is manufactured by 
Merck Sharp and Dohme, Ireland) was the first to 
be approved (Remicade will be used throughout 
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Abstract
Background: The advent of Remicade® biosimilars, Remsima®, Inflectra® and, more 
recently, Flixabi®, has brought along the potential to decrease the costs associated with this 
therapy, therefore increasing its access to a larger group of patients. However, and in order to 
assure a soft transition, one must make sure the assays and algorithms previously developed 
and optimized for Remicade perform equally well with its biosimilars. This study aimed to: 
(a) validate the utilization of Remicade-optimized therapeutic drug monitoring assays for the 
quantification of Flixabi; and (b) determine the existence of Remicade, Remsima and Flixabi 
cross-immunogenicity.
Methods: Healthy donors’ sera spiked with Remicade, Remsima and Flixabi were quantified 
using three different Remicade-quantification assays, and the reactivity of anti-Remicade and 
anti-Remsima sera to Remicade and to its biosimilars was assessed.
Results: The results show that all tested Remicade-infliximab-optimized assays measure 
Flixabi as accurately as they measure Remicade and Remsima: the intraclass correlation 
coefficients between theoretical and measured concentrations varied from 0.920 to 0.990. 
Moreover, the interassay agreement values for the same compounds were high (intraclass 
correlation coefficients varied from 0.936 to 0.995). Finally, the anti-Remicade and anti-
Remsima sera reacted to the different drugs in a similar fashion.
Conclusions: The tested assays can be used to monitor Flixabi levels. Moreover, Remicade, 
Remsima and Flixabi were shown to have a high cross-immunogenicity, which supports their 
high similarity but prevents their switching in nonresponders with antidrug antibodies.
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this article when referring to the original infliximab 
drug). Remicade is a chimeric monoclonal immu-
noglobulin G1 (IgG1) anti-TNFα antibody com-
posed of a murine variable region (25%) and a 
constant human region (75%). Its multiple mecha-
nisms of action include the reduction of lympho-
cyte and leucocyte migration to sites of 
inflammation, the downregulation of pro-inflam-
matory cytokines, and the induction of TNFα-
producing cell apoptosis, among others.4
Notwithstanding their pivotal role in the treat-
ment of IBD and other autoimmune diseases, bio-
logic therapies are substantially expensive. In fact, 
they are currently the main drivers of cost in IBD 
units.5 For that reason, biosimilars are an attrac-
tive alternative: these molecules are highly similar 
(though not identical) to their reference products 
in structural, functional, biological and clinical 
terms. With an expedited regulatory process, bio-
similars have the potential to reduce the cost of 
biological therapies by 25–40%, hence increasing 
their availability.5 Despite some controversy linked 
to the regulatory process, mostly concerning the 
extrapolation of clinical indications,6 two 
Remicade biosimilars have been approved both in 
Europe and in the USA.
Remsima® (Celltrion, Incheon, South Korea) 
and Inflectra® (Hospira, Illinois, USA) are the 
brand names of CT-P13, the first Remicade 
biosimilar approved by the European Medicine 
Agency (EMA) in September 2013 and by the 
US Food and Drug Administration (FDA) in 
April 2016. Flixabi® (Samsung Bioepsis, South 
Korea) is the brand name of SB2, which was the 
second Remicade biosimilar that received mar-
keting authorization from the EMA (in May 
2016) and from the FDA (in April 2017). Given 
the biosimilar expedited regulatory process, 
Remsima, Inflectra and Flixabi were approved 
for all the therapeutic indications of their origi-
nator drug, including CD and UC. Remsima is 
the only Remicade biosimilar for which real-
world observational data concerning IBD ther-
apy are already available: so far, these studies 
are promising, as they show no significant dif-
ferences between Remsima and Remicade in 
what concerns efficacy, safety and 
immunogenicity.7,8
There have been several attempts to optimize 
Remicade therapy in IBD patients. It is now com-
monly accepted that the rates of response and 
remission increase when a drug concentration-
guided individualized therapy is followed.3,9,10 
Given their overall similarity to Remicade®, one 
can rationally expect that this pharmacokinetic/
pharmacodynamic relationship also occurs with 
the biosimilars Remsima and Flixabi.11 The pro-
cess of adjusting the drug dosage and the infu-
sions’ interval in order to achieve a particular 
therapeutic window, within which the drug has its 
maximum efficacy with the minimum associated 
toxicity, is dependent on an accurate and system-
atic assessment of drug levels, named therapeutic 
drug monitoring (TDM). Multiple systems, 
mostly enzyme-linked immunosorbent assay 
(ELISA)-based, have been developed and are 
now available to monitor patients’ Remicade lev-
els throughout time. However, to safely employ 
TDM to tailor treatment in Flixabi- and 
Remsima-treated patients, one must determine 
whereas the systems developed and optimized to 
quantify Remicade are equally accurate in the 
quantification of its biosimilars.
Our group has previously demonstrated that a 
number of Remicade quantification methods can 
be safely applied to quantify Remsima.12 This 
study was meant to extend those analyses in order 
to include the recently-approved Flixabi. Shortly, 
our aim was to assess the efficacy, accuracy and 
interassay agreement of three Remicade quantifi-
cation assays in the monitoring of Flixabi levels. 
Additionally, we have also tested the cross-reac-
tivity of antidrug antibodies (ADAs) anti-Remi-
cade and anti-Remsima with Remicade, Remsima 
and Flixabi.
Material and methods
Spiked samples and quantification assays
Spiked samples of known Remicade, Remsima 
and Flixabi concentrations were generated by 
diluting the appropriate amount of each drug 
(Remicade, Remsima, Flixabi) into a pool of sera 
extracted from control donors. Each spiked con-
centration was repeated between six and nine 
times and analysed in duplicate. Samples were 
then quantified using one in-house assay and two 
commercially available kits: the Quantum Blue® 
infliximab: quantitative lateral flow assay 
(Buhlmann, Schönenbuch, Switzerland), hereafter 
referred to as Buhlmann; and the RIDASCREEN® 
IFX monitoring (R-Biopharm AG, Darmstadt, 
Germany), hereafter referred to as R-Biopharm.
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The in-house method was an ELISA assay com-
monly used in our laboratory and was carried out 
as previously described by Ben-Horin and col-
leagues.13–18 Briefly, serum samples were diluted 
and added to a plate precoated with TNFα 
(Peprotech, Rocky Hill, NJ, USA). After 60 min 
of incubation and an appropriate number of 
washes, a horseradish peroxidase (HRP)-labelled 
goat antihuman fragment-crystallizable fragment 
antibody (MP Biomedicals, Solon, OH, USA) 
was added and the plate was incubated for 
60 min. Afterwards, tetramethylbenzidine 
(Millipore, MA, USA) substrate was added, and 
the reaction was stopped 3 min later with 2 mol/l 
H2SO4. Finally, the samples’ absorbance was 
read at 450/540 nm, and the Remicade was quan-
tified by interpolating the absorbance values in a 
standard curve built with known concentrations 
of exogenous Remicade. The upper limit of quan-
tification was calculated as the highest concentra-
tion of the standard curve multiplied by the 
sample dilution factor used.
Concerning the Buhlmann assay, a chip card con-
taining the test information and calibration curve 
for each specific cartridge lot was supplied with 
each test kit. Briefly, serum samples were diluted 
1:20 and an 80 µl aliquot was loaded into the port 
of the test cartridge. After a 15 min reaction, the 
cartridge was read and the results were shown on 
the point-of-care Buhlmann reader display. The 
lower and upper limits of quantification were 0.4 
and 20 µg/ml, respectively.
Concerning the R-Biopharm method, the sam-
ples were diluted and added to the assay plate. 
After 60 min of incubation at 37°C and several 
washes, a conjugate was added to the plate and 
incubated for 30 min at the same temperature. 
Afterwards, the substrate was added and the reac-
tion was interrupted 10 min later by adding the 
stop reagent. The sample absorbance was read at 
450/620 nm. The manufacturer provided no 
information on the limits of quantification.
Whenever the results obtained were below or 
above the limits of quantification indicated for the 
in-house and Buhlmann methods, they were 
rounded to match those limits.
Antidrug antibodies’ cross-reactivity
Serum samples from IBD patients being treated 
with Remicade or Remsima were extracted 
immediately before an infusion. The presence of 
ADAs was determined routinely in these 
patients, and 74 serum samples were included in 
the study. Only samples positive for anti-Remi-
cade or anti-Remsima antibodies were used. The 
presence of cross-reactivity between Remicade 
and its biosimilars was determined using an in-
house procedure previously described by Ben-
Horin and colleagues.13–18 Briefly, Remicade, 
Remsima or Flixabi were added to a plate pre-
coated with TNFα. Afterwards, a diluted sample 
of serum (anti-Remicade or anti-Remsima) was 
added to the plate and incubated for 60 min at 
room temperature. Goat antihuman lambda 
chain HRP-labelled antibody (Serotec, Oxford, 
UK) was then added, followed by another room 
temperature 60 min-incubation. Finally, TMB 
(3,3’,5,5’-tetramethybenzidine, Merckmillipore, 
USA) was added and allowed to react for 6 min, 
after which the reaction was stopped with 
H2SO4. Absorbances were read at 450/540 nm, 
and the results were obtained upon interpolation 
in a standard curve of goat antihuman F(ab’)2 
fragment antibody (MP Biomedicals) and 
expressed as µg/ml-equivalent (for the purpose 
of brevity, the results are hereafter expressed as 
µg/ml). The lower limit of quantification was 
1.2 µg/ml.
This study was approved by the ethics commit-
tees of all hospitals involved and by the Portuguese 
Data Protection Authority. All patients and con-
trol donors enrolled have signed an informed 
written consent giving permission for blood sam-
ple collection for medical research.
Statistical analysis
Continuous variables were described using 
median, interquartile range, minimum and 
maximum values. The association between the-
oretical/measured concentrations, methods and 
the antidrug reactivity of Remicade and its bio-
similars was assessed by calculating the intra-
class correlation coefficient (ICC) and the 
corresponding 95% confidence intervals. 
Moreover, Bland and Altman plots were used to 
compare the different techniques. The level of 
statistical significance was set at 0.05. All statis-
tical analyses were performed using the 
Statistical Package for Social Sciences (IBM 
SPSS Statistics for Windows, Version 24.0. 
Armonk, NY, USA), whereas graphs were 
designed using Prism 7®.




The spiked samples of Remicade, Remsima and 
Flixabi were quantified using the three assays 
referred to in the material and methods section 
(Figure 1). The results show that these assays 
measure similar amounts of each compound at 
any given concentration, with the standard devia-
tions (SDs) being larger for the Buhlmann 
method. Accordingly, the mean intra-assay coef-
ficient of variation was 6.4%, 3.4% and 11.7% for 
the in-house, R-Biopharm and Buhlmann assays, 
respectively. The average recovery rates of each 
drug were higher with the R-Biopharm assay 
(105%, 102%, and 105% for Remicade, Remsima 
and Flixabi, respectively) when compared with 
the Buhlmann (91%, 87%, and 86%, respec-
tively) and the in-house methods (105%, 97%, 
and 99%, respectively).
Table 1 shows the intraclass ICCs and the aver-
age differences between the theoretical and the 
measured concentrations obtained using the dif-
ferent methods. The most accurate assay to quan-
tify Remicade and Remsima is the R-Biopharm 
(with ICCs of 0.986 and 0.990, respectively), 
whereas the most accurate method to quantify 
Flixabi is the Buhlmann (with an ICC of 0.983). 
Still, all ICCs are rather high (above 0.920) and 
therefore all methods seem to accurately measure 
the different drugs. The R-Biopharm and the in-
house methods have a negative average difference 
between theoretical and measured concentra-
tions, which means that both methods tend to 
overestimate the drugs’ concentrations, whereas 
the opposite is observed for Buhlmann. The 95% 
confidence interval (CI) of the average difference 
in Remsima and Flixabi quantified with Buhlmann 
is positive and excludes 0, which means that, in 
these cases, the underestimation is consistently 
observed throughout the entire range of tested 
concentrations.
The ICCs between the different assays are shown 
in Table 2. Values tend to be high (the minimum 
is 0.936), which means that similar concentrations 
are obtained for each compound using different 
assays. R-Biopharm is particularly close to 
Buhlmann in what comes to Remicade and 
Remsima, whereas Buhlmann is particularly close 
to the in-house method in what comes to Flixabi. 
Overall, the Buhlmann assay yields values consist-
ently lower than those obtained with R-Biopharm 
for all three drugs; on the other hand, the in-house 
method yields values consistently higher than 
those obtained with Buhlmann in what concerns 
Remicade and Flixabi. Moreover, the Bland–
Altman plots suggest that the differences between 
Figure 1. Remicade, Remsima and Flixabi-spiked 
samples measured by R-Biopharm, Buhlmann and 
the in-house assays.
Buhlmann, Quantum Blue® infliximab: quantitative lateral 
flow assay; R-Biopharm, RIDASCREEN® IFX monitoring.
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the methods increase for higher concentrations 
but rarely exceed the ±1.96 SD interval 
(Supplementary Figure 1).
Cross-immunogenicity
In order to determine the presence of cross-
immunogenicity, the three drugs were tested 
with anti-Remicade and anti-Remsima sera 
extracted from IBD patients (Figure 2). The 
results show that the amount of antisera that 
reacted to Remicade, Remsima and Flixabi was 
similar (p = 0.293 for the anti-Remicade, and 
p = 0.538 for the anti-Remsima). In fact, the 
ICCs between the different drugs’ reaction to 
anti-Remicade and anti-Remsima sera were close 
to 1.0 (Table 3).
Discussion
TDM is increasingly considered as a key step to 
optimize anti-TNFα treatment in IBD patients. 
Therefore, the advent of Remicade biosimilars 
carries along the necessity of validating the utili-
zation of Remicade-quantifying assays, which 
were optimized for Remicade, with these some-
how modified compounds. This study addressed 
the performance of three different Remicade-
optimized quantification procedures, already vali-
dated to be used with Remsima, in the assessment 
of Flixabi concentrations. Moreover, we have 
addressed the presence of cross-immunogenicity 
between Remicade, Remsima and Flixabi. The 
Buhlmann assay tested in this study is particularly 
suitable for a clinical environment as the results 
are available within 15 min of placing the sample 
into the cartridge test, which allows an immediate 
adjustment of the drug dosage. In fact, when a 
traditional ELISA method is used, the dosage 
adjustment (if needed) is usually postponed to 
the next infusion, as the results take approxi-
mately 8 h.
The three assays used, R-Biopharm, Buhlmann 
and the in-house method, seem to be almost 
equally accurate in what concerns the quantifi-
cation of Remicade and of its biosimilars. In 
fact, R-Biopharm and Buhlmann are slightly 
more accurate when measuring Remsima than 
when measuring its originator Remicade; as for 
Table 1. Intraclass correlation coefficient between the theoretical and measured concentrations.
ICC Difference
 ICC CI 95% Average CI 95%
R-Biopharm
Spiked concentrations: Remicade 0.986 0.949–0.996 −0.72 −1.82 0.38
Spiked concentrations: Remsima 0.990 0.964–0.997 −0.10 −0.98 0.77
Spiked concentrations: Flixabi 0.945 0.796–0.985 −0.69 −3.05 1.68
Buhlmann
Spiked concentrations: Remicade 0.982 0.932–0.995 0.94 −0.23 2.11
Spiked concentrations: Remsima 0.985 0.945–0.996 1.33 0.31 2.35
Spiked concentrations: Flixabi 0.983 0.938–0.996 1.28 0.14 2.41
In house
Spiked concentrations: Remicade 0.951 0.818–0.987 −1.31 −3.54 0.92
Spiked concentrations: Remsima 0.920 0.702–0.978 −0.46 −3.42 2.50
Spiked concentrations: Flixabi 0.972 0.896–0.992 −0.39 −1.99 1.22
Buhlmann, Quantum Blue® infliximab: quantitative lateral flow assay; CI, confidence interval; ICC, intraclass correlation 
coefficient; R-Biopharm, RIDASCREEN® IFX monitoring.
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the in-house method, measured values are closer 
to the theoretical concentrations in the case of 
Flixabi. Moreover, the values obtained when 
measuring each drug with the different quantifi-
cation assays are rather similar, and the differ-
ences encountered tend to be larger when the 
drugs’ concentrations are above the critical val-
ues considered to be in the therapeutic window, 
and therefore should have no effect in the 
clinical practice.3,17,19 Overall, Buhlmann slightly 
underestimates Remicade, Remsima and Flixabi 
when compared with R-Biopharm, whereas 
the in-house method slightly overestimates Remi- 
cade and Flixabi when compared with Buhlmann. 
These results consolidate what has been previ-
ously published in the literature concerning 
Remsima, that is, Remicade-optimized methods 
perform equally well when measuring biosimi-
lars’ levels.12,20–22 One can see only slight differ-
ences that are mostly likely the result of the 
small modifications in the biosimilars’ structure, 
which can be attributed to dissimilarities in the 
compounds’ biological synthesis (different cell 
lines or growth media, for instance), storage and 
transport.8,23,24
Immunogenicity is a key issue in Remicade and 
other anti-TNFα therapies: the formation of 
ADAs may directly or indirectly lower or even 
prevent the drug’s action.3 Cross-immunogenicity, 
that is, the abitility of ADAs to react against com-
pounds other than the one that stimulated their 
appearance, is of utmost important from a clinical 
point of view. In fact, when an anti-TNFα ther-
apy fails due to the presence of ADAs, one must 
Table 2. Intraclass correlation coefficient between the different methods.
ICC Difference
 ICC CI 95% Average CI 95%
Remicade
R-Biopharm–Buhlmann 0.990 0.961–0.997 1.66 0.70 2.63
R-Biopharm–in house 0.978 0.918–0.994 −0.59 −2.20 1.02
Buhlmann–in house 0.968 0.881–0.991 −2.25 −4.08 −0.43
Remsima
R-Biopharm–Buhlmann 0.995 0.980–0.999 1.44 0.79 2.08
R-Biopharm–in house 0.957 0.839–0.988 −0.35 −2.61 1.90
Buhlmann–in house 0.936 0.761–0.983 −1.79 −4.42 0.84
Flixabi
R-Biopharm–Buhlmann 0.974 0.905–0.993 1.96 0.29 3.63
R-Biopharm–in house 0.979 0.922–0.994 0.30 −1.32 1.92
Buhlmann–in house 0.986 0.946–0.996 −1.66 −2.85 −0.48
Buhlmann, Quantum Blue® infliximab: quantitative lateral flow assay; CI, confidence interval; ICC, intraclass correlation 
coefficient; R-Biopharm, RIDASCREEN® IFX monitoring.
Figure 2. Reactivity of Remicade, Remsima and 
Flixabi to anti-Remicade and anti-Remsima sera.
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consider the absence of cross-immunogenicity as 
a criterion for choosing a second anti-TNFα 
agent. Our results reveal that Remicade, Remsima 
and Flixabi react to a similar extent to anti-Rem-
icade and anti-Remsima sera. These results come 
in line with what has been previously published 
regarding the cross-immunogenicity of Remsima 
and its originator.6,22,25
This study has a couple of limitations that we 
hereafter acknowledge: the results are based on in 
vitro-spiked samples only (no clinical samples 
were used); the in vitro samples were obtained 
spiking healthy donor sera (instead of sera 
extracted from IBD patients naïve to Remicade) 
and the cross-immunogenicity assays neither 
included an anti-Flixabi serum nor an anti-TNFα 
other than Remicade as a control serum.
This study is, to our knowledge, the first to 
demonstrate that Remicade-optimized quantifi-
cation methods can be used to measure Flixabi 
levels, while consolidating the previously pub-
lished results concerning Remsima in this con-
text. In fact, our results suggest that either 
R-Biopharm, Buhlmann and the described in-
house method can be used to measure Remicade 
biosimilars Remsima and Flixabi in an accurate 
fashion. Moreover, we have demonstrated the 
existence of cross-immunogenicity between 
Remicade, Remsima and Flixabi. This not only 
reinforces the similarity among these drugs, but 
also has some clinical implications: according to 
our results, a patient medicated with Remicade 
or Remsima whose therapy fails due to the pres-
ence of ADAs would not benefit from switching 
to Remicade, Remsima or Flixabi.
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